Obsidian Therapeutics, Inc. (OBX)
| Market Cap | 753.63M |
| Revenue (ttm) | n/a |
| Net Income | -94.22M |
| EPS | -31.84 |
| Shares Out | 61.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,297 |
| Open | 12.31 |
| Previous Close | 12.22 |
| Day's Range | 12.06 - 12.67 |
| 52-Week Range | 4.30 - 49.97 |
| Beta | 2.64 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+219.67%) |
| Est. Earnings | Nov 13, 2026 |
About OBX
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that le... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OBX stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 219.67% from the latest price.
News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineer...
Obsidian Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Obsidian Therapeutics (OBX) with an Outperform rating and $32 price target
Obsidian Therapeutics participates in a conference call with William Blair
William Blair holds a conference call with CEO Madan Jagasia, M.D on September 10 at 12 pm.
Obsidian Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Obsidian Therapeutics (OBX) with an Outperform rating and $43 fair value estimate. The company is developing amsoki-cel, a potentially best-in-class, engineered tum...
Obsidian Therapeutics files to sell 29.16M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 29.16M shares of common stock. The company is not selling any…
Obsidian Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Obsidian Therapeutics (OBX) with an Outperform rating and $43 price target
Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause
10:33 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause
Obsidian Therapeutics, Inc. Common Stock trading resumes
10:43 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading resumes
Obsidian Therapeutics, Inc. Common Stock trading resumes
11:19 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading resumes
Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause
11:09 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause
Obsidian Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Obsidian Therapeutics (OBX) with a Buy rating and no price target The firm says amsoki-cel’s next-gen design combining IL-15 regulation with core needle biopsy supports…
Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause
09:49 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause
Obsidian Therapeutics, Inc. Common Stock trading resumes
09:59 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading resumes
Obsidian announces first patient enrolled in Phase 1/2 Agni-01 study
Obsidian Therapeutics (OBX) announced the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel, an engineered TIL cel...
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineer...
Obsidian Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and $42 price target Obsidian is a clinical stage biotech company advancing ...
Obsidian Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and $42 price target
Obsidian Therapeutics announces closing of transaction with Galera Therapeutics
Obsidian Therapeutics (OBX) announced the completion of its previously announced transaction with Galera Therapeutics (GRTX). The combined company will operate under the name Obsidian Therapeutics and...